GlassScriptPhysician profile
Jitha Rai-Patel
NPI 1023053402
$2,967.44
in general payments reported to CMS, 2019-2025
28 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $246 · 2022: $680 · 2023: $286 · 2024: $599 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $915.82 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.98 | 2019-2025 | Xifaxan, Trulance |
| Medtronic USA, INC. | $203.26 | 2019-2020 | |
| Janssen Biotech, INC. | $174.36 | 2019-2024 | Stelara, Simponi Aria, Tremfya |
| Conmed Corporation | $168.83 | 2025 | Conmed Biliary, Conmed Dilation, Conmed Generators |
| Ethicon US, LLC | $124.99 | 2022 | |
| Medtronic, INC. | $124.75 | 2024 | Endoflip |
| Takeda Pharmaceuticals U.S.A., INC. | $112.07 | 2019-2025 | Gattex, Entyvio |
| Cumberland Pharmaceuticals, INC. | $110.82 | 2022 | |
| Phathom Pharmaceuticals, INC. | $105.18 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $69.63 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $58.19 | 2023 | Stelara |
| Celgene Corporation | $57.64 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $53.83 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $49.11 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $40.59 | 2019-2020 | |
| Ardelyx, INC. | $38.64 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $34.26 | 2025 | Rezdiffra |
| Lilly USA, LLC | $32.77 | 2025 | Omvoh |
| Pfizer INC. | $29.74 | 2019-2023 | |
| Braintree Laboratories, INC. | $28.13 | 2019-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $27.52 | 2020-2023 | Ocaliva |
| Digestive Care, INC. | $18.76 | 2022 | |
| Exact Sciences Corporation | $18.21 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $16.16 | 2025 | Wegovy |
| Genzyme Corporation | $15.05 | 2022 | |
| Allergan, INC. | $12.46 | 2019 | |
| Daiichi Sankyo INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitha Rai-Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.